Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients

Arthritis and Rheumatism

Volumn 54, Issue 8, 2006, Pages 2568-2576

  Bucciarelli, Silvia ^a   Espinosa, Gerard ^a   Cervera, Ricard ^a   Erkan, Doruk ^b   Gómez Puerta, José A ^a   Ramos Casals, Manuel ^a   Font, Josep ^a   Asherson, Ronald A ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN DISEASE; BRAIN HEMORRHAGE; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CAUSE OF DEATH; CLINICAL FEATURE; CONVALESCENCE; DISEASE ASSOCIATION; FEMALE; HEART DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REGISTER; STROKE; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; CAUSE OF DEATH; COMORBIDITY; FEMALE; HUMANS; MALE; MORTALITY; PROGNOSIS; REGISTRIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33746993589     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22018     Document Type: Article

References (16)

1. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508-12.
2. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207.
3. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001;80:355-76.
4. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4.
5. Piette JC, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y. The catastrophic antiphospholipid syndrome-Asherson's syndrome. Ann Med Interne (Paris) 2003;154:195-6.
6. Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome in 2004. Autoimmun Rev 2005;4:48-54.
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al, and the Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
8. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? [review]. Arthritis Rheum 2003;48:3320-7.
9. Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003;62:530-3.
10. Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 2005;33:11-7.
11. Harris EN, Pierangeli S. Primary, secondary, catastrophic antiphospholipid syndrome: is there a difference? Thromb Res 2004;114:357-61.
12. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:237-40.
13. Burcoglu-O'ral A, Erkan D, Asherson RA. Treatment of catastrophic antiphospholipid syndrome (CAPS) with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 2002; 29:2006-11.
14. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 2004;202:145-56.
15. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996;24:1408-16.
16. Ren J, Wu S. A burning issue: do sepsis and systemic inflammatory response syndrome (SIRS) directly contribute to cardiac dysfunction? Front Biosci 2006;11:15-22.